The EGFR C797S mutation in TKI-naive NSCLC
Not Applicable
- Conditions
- on small cell lung cancer
- Registration Number
- JPRN-UMIN000029017
- Lead Sponsor
- Fukushima Medical University
- Brief Summary
o concurrent C797S mutation with known EGFR gene mutation was identified. T790M mutation was identified in 12 patients (4.9%). ERBB2 or MET gene amplification was found in a few patients (0.0-0.4%). MDM2 gene amplification was associated with tumor recurrence and shorter progression free survival for first or second generation EGFR-TKIs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 248
Inclusion Criteria
Not provided
Exclusion Criteria
EGFR-TKI administration before specimen collection
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of EGFR-C797S mutation in EGFR TKI naive NSCLC
- Secondary Outcome Measures
Name Time Method EGFR-T790M mutation, allelic pattern of T790M and C797S mutation, clinicopathological features, HER2 amplification, and MET amplification